Squarepoint’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $760K | Sell |
28,108
-25,448
| -48% | -$855K | ﹤0.01% | 3004 |
|
|
2025
Q4 | $2.29M | Sell |
53,556
-119,082
| -69% | -$4.49M | ﹤0.01% | 1966 |
|
|
2025
Q3 | $4.89M | Buy |
172,638
+136,423
| +377% | +$4.08M | ﹤0.01% | 1487 |
|
|
2025
Q2 | $678K | Buy |
36,215
+14,135
| +64% | +$268K | ﹤0.01% | 3009 |
|
|
2025
Q1 | $397K | Sell |
22,080
-41,336
| -65% | -$839K | ﹤0.01% | 3503 |
|
|
2024
Q4 | $1.07M | Buy |
63,416
+18,159
| +40% | +$348K | ﹤0.01% | 3011 |
|
|
2024
Q3 | $732K | Sell |
45,257
-35,653
| -44% | -$419K | ﹤0.01% | 2838 |
|
|
2024
Q2 | $665K | Buy |
80,910
+21,078
| +35% | +$221K | ﹤0.01% | 2866 |
|
|
2024
Q1 | $886K | Buy |
59,832
+27,453
| +85% | +$370K | ﹤0.01% | 2678 |
|
|
2023
Q4 | $469K | Buy |
+32,379
| New | +$331K | ﹤0.01% | 3050 |
|
|
2023
Q3 | – | Sell |
-1,993
| Closed | -$25.7K | – | 4166 |
|
|
2023
Q2 | $25.7K | Buy |
+1,993
| New | +$26.9K | ﹤0.01% | 3479 |
|
|
2023
Q1 | – | Sell |
-2,801
| Closed | -$42K | – | 3717 |
|
|
2022
Q4 | $42K | Sell |
2,801
-53,881
| -95% | -$494K | ﹤0.01% | 3070 |
|
|
2022
Q3 | $669K | Buy |
+56,682
| New | +$767K | ﹤0.01% | 2043 |
|
|
2022
Q2 | – | Sell |
-1,764
| Closed | -$53K | – | 3289 |
|
|
2022
Q1 | $53K | Sell |
1,764
-13,518
| -88% | -$366K | ﹤0.01% | 2675 |
|
|
2021
Q4 | $405K | Sell |
15,282
-18,674
| -55% | -$563K | ﹤0.01% | 2286 |
|
|
2021
Q3 | $1.23M | Buy |
33,956
+7,805
| +30% | +$307K | ﹤0.01% | 1459 |
|
|
2021
Q2 | $1.14M | Buy |
26,151
+16,237
| +164% | +$613K | ﹤0.01% | 1548 |
|
|
2021
Q1 | $339K | Buy |
+9,914
| New | +$393K | ﹤0.01% | 2314 |
|
|
2020
Q4 | – | Sell |
-22,385
| Closed | -$537K | – | 3207 |
|
|
2020
Q3 | $537K | Sell |
22,385
-14,249
| -39% | -$350K | 0.01% | 1386 |
|
|
2020
Q2 | $670K | Buy |
36,634
+24,048
| +191% | +$433K | 0.01% | 1147 |
|
|
2020
Q1 | $196K | Sell |
12,586
-49,280
| -80% | -$1.05M | 0.01% | 1485 |
|
|
2019
Q4 | $1.32M | Sell |
61,866
-48,381
| -44% | -$996K | 0.01% | 1163 |
|
|
2019
Q3 | $2.06M | Buy |
110,247
+59,851
| +119% | +$1.24M | 0.02% | 837 |
|
|
2019
Q2 | $1.31M | Buy |
50,396
+16,025
| +47% | +$362K | 0.01% | 1098 |
|
|
2019
Q1 | $883K | Buy |
34,371
+32,754
| +2,026% | +$749K | 0.01% | 1168 |
|
|
2018
Q4 | $37K | Sell |
1,617
-3,042
| -65% | -$85.8K | ﹤0.01% | 1854 |
|
|
2018
Q3 | $150K | Sell |
4,659
-4,323
| -48% | -$130K | ﹤0.01% | 1829 |
|
|
2018
Q2 | $254K | Buy |
+8,982
| New | +$320K | ﹤0.01% | 1451 |
|
|
2017
Q4 | – | Sell |
-1,294
| Closed | -$33K | – | 2303 |
|
|
2017
Q3 | $33K | Buy |
+1,294
| New | +$31.5K | ﹤0.01% | 1574 |
|
|
2017
Q2 | – | Sell |
-2,939
| Closed | -$97K | – | 1761 |
|
|
2017
Q1 | $97K | Sell |
2,939
-5,731
| -66% | -$146K | ﹤0.01% | 1417 |
|
|
2016
Q4 | $206K | Buy |
+8,670
| New | +$248K | 0.01% | 1424 |
|
Other funds holding RIGL
AC
VCM
Squarepoint's RIGL Position: Q1 2026 in Review
Squarepoint reduced its Rigel Pharmaceuticals (RIGL) stake by 48% in Q1 2026, selling an estimated $855K and leaving 28,108 shares worth $760K. The position accounts for ﹤0.01% of the portfolio, ranked #3004.
Squarepoint first reported a position in RIGL in Q4 2016 and has held it in 31 quarters since. The position peaked at $4.89M in Q3 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Squarepoint held 28,108 shares of Rigel Pharmaceuticals worth $760K as of Q1 2026.
- Squarepoint sold 25,448 Rigel Pharmaceuticals shares in Q1 2026, an estimated $855K.
- Rigel Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3004 holding.
- Squarepoint first reported a position in Rigel Pharmaceuticals in Q4 2016 and has held it in 31 quarters since.
- Squarepoint's Rigel Pharmaceuticals position peaked at $4.89M in Q3 2025.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.